Signaling networks in MS: A systems-based approach to developing new pharmacological therapies

Multiple Sclerosis Journal

Volumn 21, Issue 2, 2015, Pages 138-146

  Kotelnikova, Ekaterina ^a,k   Bernardo Faura, Marti ^b   Silberberg, Gilad ^c   Kiani, Narsis A ^c   Messinis, Dimitris ^d   Melas, Ioannis N ^b,d,e   Artigas, Laura ^f   Schwartz, Elena ^g   Mazo, Ilya ^g   Masso, Mar ^e   Alexopoulos, Leonidas G ^d,e   Mas, Jose Manuel ^f   Olsson, Tomas ^c   Tegner, Jesper ^c   Martin, Roland ⁱ   Zamora, Albert ^h   Paul, Friedemann ^j   Saez Rodriguez, Julio ^b   Villoslada, Pablo ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d PROTATONCE LTD   (Greece)

^e NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^f Anaxomics Biotech   (Spain)

^g Ariadne Diagnostics LLC   (United States)

^h Bionure Farma Accure Therapeutics SL   (Spain)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k INSTITUTE FOR INFORMATION TRANSMISSION PROBLEMS   (Russian Federation)

more..

Author keywords

Drug discovery; Multiple sclerosis; Pathways; Signaling; Systems biology

Indexed keywords

BETA INTERFERON; CATECHIN; CYTOKINE; EPIGALLOCATECHIN GALLATE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; VITAMIN D;

APOPTOSIS; CENTRAL NERVOUS SYSTEM; COMPUTATIONAL FLUID DYNAMICS; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE SYSTEM; MATHEMATICAL MODEL; MICROGLIA; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SYSTEM ANALYSIS; SYSTEMS BIOLOGY; TEA; VITAMIN SUPPLEMENTATION; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

DRUG DISCOVERY; HUMANS; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION;

EID: 84923116236     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514543339     Document Type: Review

References (38)

1. Villoslada P, Baranzini S. Data integration and systems biology approaches for biomarker discovery: Challenges and opportunities for multiple sclerosis. J Neuroimmunol. 2012 ; 248: 58-65
2. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: Prospects and promise. Ann Neurol. 2013 ; 74: 317-327
3. Villoslada P, Steinman L, Baranzini SE. Systems biology and its application to the understanding of neurological diseases. Ann Neurol. 2009 ; 65: 124-139
4. Clermont G, Auffray C, Moreau Y, et al. Bridging the gap between systems biology and medicine. Genome Med. 2009 ; 1: 88
5. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
6. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013 ; 45: 1353-1360
7. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet. 2013 ; 92: 854-865
8. Palacios R, Goni J, Martinez-Forero I, et al. A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One. 2007 ; 2: e1222
9. Zhang Y, Argaw AT, Gurfein BT, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci U S A. 2009 ; 106: 19162-19167
10. Bassil R, Zhu B, Lahoud Y, et al. Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. J Immunol. 2011 ; 187: 2322-2328
11. Ascherio A, Marrie RA. Vitamin D in MS: A vitamin for 4 seasons. Neurology. 2012 ; 79: 208-210
12. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: What have we learnt from animal models. Exp Neurol. 2010 ; 225: 2-8
13. Mähler A, Mandel S, Lorenz M, et al. Epigallocatechin-3-gallate: A useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. EPMA J. 2013 ; 4: 5
14. Suhs KW, Hein K, Sattler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012 ; 72: 199-210
15. Moreno B, Lopez I, Fernández-Díez B, et al. Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosine. PLoS One. 2014 ; 9: e90671
16. Rudick RA, Mi S, Sandrock AW. LINGO-1 antagonists as therapy for multiple sclerosis: In vitro and in vivo evidence. Expert Opin Biol Ther. 2008 ; 8: 1561-1570
17. Sigal A, Milo R, Cohen A, et al. Variability and memory of protein levels in human cells. Nature. 2006 ; 444: 643-646
18. Blüthgen N, Legewie S. Robustness of signal transduction pathways. Cell Mol Life Sci. 2013 ; 70: 2259-2269
19. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar A, et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol. 2008 ; 38: 576-586
20. Arnett HA, Mason J, Marino M, et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 2001 ; 4: 1116-1122
21. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology. 1999 ; 53: 457-465
22. Aldridge BB, Saez-Rodriguez J, Muhlich JL, et al. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput Biol. 2009 ; 5: e1000340
23. Kholodenko BN, Hancock JF, Kolch W. Signalling ballet in space and time. Nat Rev Mol Cell Biol. 2010 ; 11: 414-426
24. Morris MK, Chi A, Melas IN, et al. Phosphoproteomics in drug discovery. Drug Discov Today. 2014 ; 19: 425-432
25. Saez-Rodriguez J, Alexopoulos LG, Zhang M, et al. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res. 2011 ; 71: 5400-5411
26. Kholodenko B, Yaffe MB, Kolch W. Computational approaches for analyzing information flow in biological networks. Sci Signal. 2012 ; 5: re1
27. MacNamara A, Terfve C, Henriques D, et al. State-time spectrum of signal transduction logic models. Phys Biol. 2012 ; 9: 045003
28. Saez-Rodriguez J, Alexopoulos LG, Epperlein J, et al. Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol Syst Biol. 2009 ; 5: 331
29. Tegner JN, Compte A, Auffray C, et al. Computational disease modeling - fact or fiction?. BMC Syst Biol. 2009 ; 3: 56
30. Spencer SL, Sorger PK. Measuring and modeling apoptosis in single cells. Cell. 2011 ; 144: 926-939
31. Gomez-Cabrero D, Compte A, Tegner J. Workflow for generating competing hypothesis from models with parameter uncertainty. Interface Focus. 2011 ; 1: 438-449
32. Pertsovskaya I, Abad E, Domedel-Puig N, et al. Transient oscillatory dynamics of interferon beta signaling in macrophages. BMC Syst Biol. 2013 ; 7: 59
33. Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012 ; 11: 191-200
34. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 299-308
35. Fitzgerald JB, Schoeberl B, Nielsen UB, et al. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006 ; 2: 458-466
36. Lehár J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007 ; 3: 80
37. Zhao S, Nishimura T, Chen Y, et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013 ; 5: 206ra140
38. Klipp E, Wade RC, Kummer U. Biochemical network-based drug-target prediction. Curr Op Biotech. 2010 ; 21: 511-516